Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. Show more
Location: 80 Guest Street, Boston, MA, 02135, United States | Website: https://www.aurabiosciences.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
393.8M
52 Wk Range
$4.34 - $12.38
Previous Close
$6.34
Open
$6.34
Volume
100,596
Day Range
$6.20 - $6.42
Enterprise Value
232.8M
Cash
177.3M
Avg Qtr Burn
-20.84M
Insider Ownership
1.98%
Institutional Own.
84.55%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Belzupacap Sarotalocan (Bel-sar) Details Early-Stage Choroidal Melanoma | Phase 3 Update | |
Belzupacap Sarotalocan (Bel-sar) (Suprachoroidal (SC) Administration) Details 1L Early-Stage Choroidal Melanoma | Phase 2 Update | |
Belzupacap Sarotalocan (Bel-sar) (AU-011) Details Non-Muscle-Invasive Bladder Cancer (NMIBC) | Phase 1/2 Data readout |